Literature DB >> 15363066

Nerve conduction abnormalities in the trembler-j mouse: a model for Charcot-Marie-Tooth disease type 1A?

Gregg D Meekins1, Michael J Emery, Michael D Weiss.   

Abstract

The trembler-j mouse is a spontaneously occurring, demyelinating mutant secondary to a point mutation involving a leucine for proline substitution in the first transmembrane domain of the peripheral-myelin protein-22 (PMP-22) gene. It is considered to be a model for Charcot-Marie-Tooth disease type 1A (CMT1A), largely based upon pathologic observations. However, functional studies demonstrating homology with CMT1A patients have not been documented. Sciatic nerve conduction was performed on 30 and 72-day-old wildtype and trembler-j mice in a blinded fashion. The findings in the mutants in both age groups were consistent with profound demyelination. Trembler-j mice appear to have a greater degree of motor nerve conduction slowing relative to human studies involving patients with PMP-22 gene duplication. Functionally, the trembler-j is a good murine model for CMT1A associated with an identical point mutation but may represent a more severe disease phenotype than CMT1A secondary to PMP-22 gene duplication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363066     DOI: 10.1111/j.1085-9489.2004.09310.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  9 in total

1.  Structural and Functional Abnormalities of the Neuromuscular Junction in the Trembler-J Homozygote Mouse Model of Congenital Hypomyelinating Neuropathy.

Authors:  Alexandra N Scurry; Dante J Heredia; Cheng-Yuan Feng; Gregory B Gephart; Grant W Hennig; Thomas W Gould
Journal:  J Neuropathol Exp Neurol       Date:  2016-02-25       Impact factor: 3.685

2.  Injection of the sciatic nerve with TMEV: a new model for peripheral nerve demyelination.

Authors:  Kristen M Drescher; Steven M Tracy
Journal:  Virology       Date:  2006-10-09       Impact factor: 3.616

3.  A novel system to accelerate the progression of nerve degeneration in transgenic mouse models of neuropathies.

Authors:  Osefame Ewaleifoh; Minh Trinh; John W Griffin; Thien Nguyen
Journal:  Exp Neurol       Date:  2012-06-09       Impact factor: 5.330

4.  Long-term analyses of innervation and neuromuscular integrity in the Trembler-J mouse model of Charcot-Marie-Tooth disease.

Authors:  Jessica Renee Nicks; Sooyeon Lee; Kathryne Ann Kostamo; Andrew Benford Harris; Amanda M Sookdeo; Lucia Notterpek
Journal:  J Neuropathol Exp Neurol       Date:  2013-10       Impact factor: 3.685

5.  Rapamycin improves peripheral nerve myelination while it fails to benefit neuromuscular performance in neuropathic mice.

Authors:  Jessica Nicks; Sooyeon Lee; Andrew Harris; Darin J Falk; Adrian G Todd; Karla Arredondo; William A Dunn; Lucia Notterpek
Journal:  Neurobiol Dis       Date:  2014-07-09       Impact factor: 5.996

Review 6.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

7.  Rer1 and calnexin regulate endoplasmic reticulum retention of a peripheral myelin protein 22 mutant that causes type 1A Charcot-Marie-Tooth disease.

Authors:  Taichi Hara; Yukiko Hashimoto; Tomoko Akuzawa; Rika Hirai; Hisae Kobayashi; Ken Sato
Journal:  Sci Rep       Date:  2014-11-11       Impact factor: 4.379

8.  Differentiation of Human Tonsil-Derived Mesenchymal Stem Cells into Schwann-Like Cells Improves Neuromuscular Function in a Mouse Model of Charcot-Marie-Tooth Disease Type 1A.

Authors:  Saeyoung Park; Namhee Jung; Seoha Myung; Yoonyoung Choi; Ki Wha Chung; Byung-Ok Choi; Sung-Chul Jung
Journal:  Int J Mol Sci       Date:  2018-08-14       Impact factor: 5.923

9.  AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy.

Authors:  Zarife Sahenk; Gloria Galloway; Kelly Reed Clark; Vinod Malik; Louise R Rodino-Klapac; Brian K Kaspar; Lei Chen; Cilwyn Braganza; Chrystal Montgomery; Jerry R Mendell
Journal:  Mol Ther       Date:  2013-10-28       Impact factor: 11.454

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.